Refractory Takayasu arteritis successfully treated with rituximab: case-based review.
Identifieur interne : 000921 ( Main/Exploration ); précédent : 000920; suivant : 000922Refractory Takayasu arteritis successfully treated with rituximab: case-based review.
Auteurs : Tomoyuki Mutoh [Japon] ; Tomonori Ishii [Japon] ; Tsuyoshi Shirai [Japon] ; Kanae Akita [Japon] ; Yukiko Kamogawa [Japon] ; Yoko Fujita [Japon] ; Hiroko Sato [Japon] ; Yuko Shirota [Japon] ; Hiroshi Fujii [Japon] ; Hideo Harigae [Japon]Source :
- Rheumatology international [ 1437-160X ] ; 2019.
Descripteurs français
- KwdFr :
- Abatacept (usage thérapeutique), Adulte, Anticorps monoclonaux humanisés (usage thérapeutique), Facteurs immunologiques (usage thérapeutique), Humains, Infliximab (usage thérapeutique), Maladie de Takayashu (traitement médicamenteux), Mâle, Rituximab (usage thérapeutique), Résultat thérapeutique, Échec thérapeutique, Étanercept (usage thérapeutique).
- MESH :
- traitement médicamenteux : Maladie de Takayashu.
- usage thérapeutique : Abatacept, Anticorps monoclonaux humanisés, Facteurs immunologiques, Infliximab, Rituximab, Étanercept.
- Adulte, Humains, Mâle, Résultat thérapeutique, Échec thérapeutique.
English descriptors
- KwdEn :
- Abatacept (therapeutic use), Adult, Antibodies, Monoclonal, Humanized (therapeutic use), Etanercept (therapeutic use), Humans, Immunologic Factors (therapeutic use), Infliximab (therapeutic use), Male, Rituximab (therapeutic use), Takayasu Arteritis (drug therapy), Treatment Failure, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Abatacept, Antibodies, Monoclonal, Humanized, Etanercept, Immunologic Factors, Infliximab, Rituximab.
- drug therapy : Takayasu Arteritis.
- Adult, Humans, Male, Treatment Failure, Treatment Outcome.
Abstract
Takayasu arteritis (TAK) is a subtype of the large-vessel vasculitis, affecting the aorta and its major branches. Although T cell-mediated autoimmunity is mainly involved in vascular inflammation, in recent years, accumulating evidence suggests the important role of B cells in the pathogenesis and effectiveness of B-cell-targeted therapy with rituximab (RTX), a chimeric anti-CD20 monoclonal antibody in refractory TAK. Herein, we report for the first time a case involving a 34-year-old man with TAK who was refractory to four different biologic agents, such as one selective T-cell co-stimulation modulator (abatacept), one anti-interleukin-6 receptor monoclonal antibody (tocilizumab), and two tumor necrosis factor-α inhibitors (infliximab and etanercept), but eventually achieved remission with RTX. He received a total of six courses of RTX, and doses of prednisolone and methotrexate were tapered without relapse. The current case provided further evidence to the potential role of RTX therapy in patients with refractory TAK, and its efficacy needs to be validated in a controlled trial.
DOI: 10.1007/s00296-019-04390-w
PubMed: 31388749
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000309
- to stream PubMed, to step Curation: 000309
- to stream PubMed, to step Checkpoint: 000371
- to stream Ncbi, to step Merge: 002246
- to stream Ncbi, to step Curation: 002246
- to stream Ncbi, to step Checkpoint: 002246
- to stream Main, to step Merge: 000921
- to stream Main, to step Curation: 000921
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Refractory Takayasu arteritis successfully treated with rituximab: case-based review.</title><author><name sortKey="Mutoh, Tomoyuki" sort="Mutoh, Tomoyuki" uniqKey="Mutoh T" first="Tomoyuki" last="Mutoh">Tomoyuki Mutoh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Ishii, Tomonori" sort="Ishii, Tomonori" uniqKey="Ishii T" first="Tomonori" last="Ishii">Tomonori Ishii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. tishii@med.tohoku.ac.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Shirai, Tsuyoshi" sort="Shirai, Tsuyoshi" uniqKey="Shirai T" first="Tsuyoshi" last="Shirai">Tsuyoshi Shirai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Akita, Kanae" sort="Akita, Kanae" uniqKey="Akita K" first="Kanae" last="Akita">Kanae Akita</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Kamogawa, Yukiko" sort="Kamogawa, Yukiko" uniqKey="Kamogawa Y" first="Yukiko" last="Kamogawa">Yukiko Kamogawa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Fujita, Yoko" sort="Fujita, Yoko" uniqKey="Fujita Y" first="Yoko" last="Fujita">Yoko Fujita</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Sato, Hiroko" sort="Sato, Hiroko" uniqKey="Sato H" first="Hiroko" last="Sato">Hiroko Sato</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Shirota, Yuko" sort="Shirota, Yuko" uniqKey="Shirota Y" first="Yuko" last="Shirota">Yuko Shirota</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai</wicri:regionArea><wicri:noRegion>Sendai</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, Hiroshi" sort="Fujii, Hiroshi" uniqKey="Fujii H" first="Hiroshi" last="Fujii">Hiroshi Fujii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Harigae, Hideo" sort="Harigae, Hideo" uniqKey="Harigae H" first="Hideo" last="Harigae">Hideo Harigae</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31388749</idno><idno type="pmid">31388749</idno><idno type="doi">10.1007/s00296-019-04390-w</idno><idno type="wicri:Area/PubMed/Corpus">000309</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000309</idno><idno type="wicri:Area/PubMed/Curation">000309</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000309</idno><idno type="wicri:Area/PubMed/Checkpoint">000371</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000371</idno><idno type="wicri:Area/Ncbi/Merge">002246</idno><idno type="wicri:Area/Ncbi/Curation">002246</idno><idno type="wicri:Area/Ncbi/Checkpoint">002246</idno><idno type="wicri:Area/Main/Merge">000921</idno><idno type="wicri:Area/Main/Curation">000921</idno><idno type="wicri:Area/Main/Exploration">000921</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Refractory Takayasu arteritis successfully treated with rituximab: case-based review.</title><author><name sortKey="Mutoh, Tomoyuki" sort="Mutoh, Tomoyuki" uniqKey="Mutoh T" first="Tomoyuki" last="Mutoh">Tomoyuki Mutoh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Ishii, Tomonori" sort="Ishii, Tomonori" uniqKey="Ishii T" first="Tomonori" last="Ishii">Tomonori Ishii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. tishii@med.tohoku.ac.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Shirai, Tsuyoshi" sort="Shirai, Tsuyoshi" uniqKey="Shirai T" first="Tsuyoshi" last="Shirai">Tsuyoshi Shirai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Akita, Kanae" sort="Akita, Kanae" uniqKey="Akita K" first="Kanae" last="Akita">Kanae Akita</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Kamogawa, Yukiko" sort="Kamogawa, Yukiko" uniqKey="Kamogawa Y" first="Yukiko" last="Kamogawa">Yukiko Kamogawa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Fujita, Yoko" sort="Fujita, Yoko" uniqKey="Fujita Y" first="Yoko" last="Fujita">Yoko Fujita</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Sato, Hiroko" sort="Sato, Hiroko" uniqKey="Sato H" first="Hiroko" last="Sato">Hiroko Sato</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Shirota, Yuko" sort="Shirota, Yuko" uniqKey="Shirota Y" first="Yuko" last="Shirota">Yuko Shirota</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai</wicri:regionArea><wicri:noRegion>Sendai</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, Hiroshi" sort="Fujii, Hiroshi" uniqKey="Fujii H" first="Hiroshi" last="Fujii">Hiroshi Fujii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author><author><name sortKey="Harigae, Hideo" sort="Harigae, Hideo" uniqKey="Harigae H" first="Hideo" last="Harigae">Hideo Harigae</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574</wicri:regionArea><wicri:noRegion>980-8574</wicri:noRegion></affiliation></author></analytic><series><title level="j">Rheumatology international</title><idno type="eISSN">1437-160X</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (therapeutic use)</term><term>Adult</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Etanercept (therapeutic use)</term><term>Humans</term><term>Immunologic Factors (therapeutic use)</term><term>Infliximab (therapeutic use)</term><term>Male</term><term>Rituximab (therapeutic use)</term><term>Takayasu Arteritis (drug therapy)</term><term>Treatment Failure</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept (usage thérapeutique)</term><term>Adulte</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Humains</term><term>Infliximab (usage thérapeutique)</term><term>Maladie de Takayashu (traitement médicamenteux)</term><term>Mâle</term><term>Rituximab (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Échec thérapeutique</term><term>Étanercept (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Etanercept</term><term>Immunologic Factors</term><term>Infliximab</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Takayasu Arteritis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Takayashu</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Facteurs immunologiques</term><term>Infliximab</term><term>Rituximab</term><term>Étanercept</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Humans</term><term>Male</term><term>Treatment Failure</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Échec thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Takayasu arteritis (TAK) is a subtype of the large-vessel vasculitis, affecting the aorta and its major branches. Although T cell-mediated autoimmunity is mainly involved in vascular inflammation, in recent years, accumulating evidence suggests the important role of B cells in the pathogenesis and effectiveness of B-cell-targeted therapy with rituximab (RTX), a chimeric anti-CD20 monoclonal antibody in refractory TAK. Herein, we report for the first time a case involving a 34-year-old man with TAK who was refractory to four different biologic agents, such as one selective T-cell co-stimulation modulator (abatacept), one anti-interleukin-6 receptor monoclonal antibody (tocilizumab), and two tumor necrosis factor-α inhibitors (infliximab and etanercept), but eventually achieved remission with RTX. He received a total of six courses of RTX, and doses of prednisolone and methotrexate were tapered without relapse. The current case provided further evidence to the potential role of RTX therapy in patients with refractory TAK, and its efficacy needs to be validated in a controlled trial.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Mutoh, Tomoyuki" sort="Mutoh, Tomoyuki" uniqKey="Mutoh T" first="Tomoyuki" last="Mutoh">Tomoyuki Mutoh</name></noRegion><name sortKey="Akita, Kanae" sort="Akita, Kanae" uniqKey="Akita K" first="Kanae" last="Akita">Kanae Akita</name><name sortKey="Fujii, Hiroshi" sort="Fujii, Hiroshi" uniqKey="Fujii H" first="Hiroshi" last="Fujii">Hiroshi Fujii</name><name sortKey="Fujita, Yoko" sort="Fujita, Yoko" uniqKey="Fujita Y" first="Yoko" last="Fujita">Yoko Fujita</name><name sortKey="Harigae, Hideo" sort="Harigae, Hideo" uniqKey="Harigae H" first="Hideo" last="Harigae">Hideo Harigae</name><name sortKey="Ishii, Tomonori" sort="Ishii, Tomonori" uniqKey="Ishii T" first="Tomonori" last="Ishii">Tomonori Ishii</name><name sortKey="Kamogawa, Yukiko" sort="Kamogawa, Yukiko" uniqKey="Kamogawa Y" first="Yukiko" last="Kamogawa">Yukiko Kamogawa</name><name sortKey="Sato, Hiroko" sort="Sato, Hiroko" uniqKey="Sato H" first="Hiroko" last="Sato">Hiroko Sato</name><name sortKey="Shirai, Tsuyoshi" sort="Shirai, Tsuyoshi" uniqKey="Shirai T" first="Tsuyoshi" last="Shirai">Tsuyoshi Shirai</name><name sortKey="Shirota, Yuko" sort="Shirota, Yuko" uniqKey="Shirota Y" first="Yuko" last="Shirota">Yuko Shirota</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000921 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000921 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31388749
|texte= Refractory Takayasu arteritis successfully treated with rituximab: case-based review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31388749" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |